ADC resistance in bladder cancer is multifactorial, review finds, with no validated overcoming strategy
New research identifies why some bladder cancer drugs stop working
This systematic review examines mechanisms of resistance to antibody-drug conjugates in locally advanced or metastatic urothelial carcinoma.…
Doctors are uncovering the complex reasons why certain bladder cancer treatments lose their power, helping pave the way for more precise the…
HER2-low breast cancer shows distinct survival trajectories versus HER2-positive in systematic review
HER2-Low Status Shows Distinct Survival Paths in Breast Cancer
This systematic review of 10 trials synthesizes evidence on survival outcomes in HER2-low versus HER2-positive breast cancer. The authors re…
New analysis shows that HER2-low breast cancer tumors follow different survival paths than HER2-positive tumors, which may help doctors plan…
Splicing-derived neoantigens provide diverse target classes for T-cell and antibody-based cancer immunotherapies
Splicing-Derived Neoantigens Offer New Targets for Cancer Immunotherapy
This systematic review explores splicing-derived neoantigens as potential targets for cancer immunotherapy. The review identifies two major …
New research identifies splicing-derived neoantigens as a promising source of specific targets for T-cell and antibody-based cancer treatmen…
Trop-2 directed ADCs improve progression free survival in high Trop-2 expression breast cancer patients
Trop-2 Protein Levels May Influence Breast Cancer Treatment Outcomes
This meta-analysis and retrospective analysis evaluate the impact of Trop-2 protein and gene expression on outcomes for patients with breast…
New analysis suggests Trop-2 protein levels may help predict how patients with breast cancer respond to specific antibody-drug conjugate tre…
Systematic Review Maps Exponential Growth of Antibody-Drug Conjugate Trials in Lung Cancer
Global review shows antibody-drug conjugates for lung cancer trials are growing fast
This systematic review of 466 global trials documents exponential growth in antibody-drug conjugate (ADC) trials for lung cancer, from 1 in …
A global review of lung cancer trials shows antibody-drug conjugate research is expanding rapidly, with more than 100 new trials registered …
Comprehensive review of ocular toxicity risks across all currently approved antibody-drug conjugates
Cancer drugs may harm your vision without warning
This comprehensive review synthesizes evidence regarding ocular toxicity associated with all currently approved antibody-drug conjugates (AD…
Popular cancer drugs can hurt your eyes, yet doctors often miss these side effects until vision suffers significantly.
Review of immunotherapy innovations for triple-negative breast cancer survival
New Hope for Tough-to-Treat Breast Cancer
This narrative review examines immunotherapy innovations, including immune checkpoint inhibitors and combination strategies, for patients wi…
This approach may change how doctors treat one of the hardest forms of breast cancer.